دورية أكاديمية
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
| العنوان: | Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT |
|---|---|
| المؤلفون: | Nagler, A., Baron, Frédéric, Labopin, M., Polge, E., Esteve, J., Bazarbachi, A., Brissot, E., Bug, G., Ciceri, F., Giebel, S., Gilleece, M. H., Gorin, N.-C., Lanza, F., Peric, Z., Ruggeri, A., Sanz, J., Savani, B. N., Schmid, C., Shouval, R., Spyridonidis, A., Versluis, J., Mohty, M. |
| المصدر: | Bone Marrow Transplantation, 56, 218-224 (2021) |
| بيانات النشر: | Springer Nature, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundred had a formal strategy for routine MRD assessment, 91 for both ALL and AML. For ALL (n = 95), assessing MRD has been routine practice starting from 2010 (range, 1990–2019). Techniques used for MRD assessment consisted of PCR techniques alone (n = 27), multiparameter flow cytometry (MFC, n = 16), both techniques (n = 43), next-generation sequencing (NGS) + PCR (n = 2), or PCR + MFC + NGS (n = 7). The majority of centers assessed MRD every 2–3 months for 2 (range, 1-until relapse) years. For AML, assessing MRD was routine in 92 centers starting in 2010 (range 1990–2019). Assessment of MRD was by PCR (n = 23), MFC (n = 13), both PCR and MFC (n = 39), both PCR and NGS (n = 3), and by all three techniques (n = 14). The majority assesses MRD for AML every 2–3 months for 2 (range, 1-until relapse) years. This survey is the first step in the aim to include MRD status as a routine registry capture parameter in acute leukemia. © 2020, The Author(s), under exclusive licence to Springer Nature Limited. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article peer reviewed |
| اللغة: | English |
| Relation: | urn:issn:0268-3369; urn:issn:1476-5365 |
| DOI: | 10.1038/s41409-020-01005-y |
| URL الوصول: | https://orbi.uliege.be/handle/2268/250601 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.250601 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1038/s41409-020-01005-y |
|---|